|  | Diet & Nutrition | NutriSystem

Polycythemia Vera Treatment: Standard Options and the Role of Phosphorus-32

Standard Management of Polycythemia Vera (PV)

PV is a myeloproliferative neoplasm causing overproduction of red blood cells. Treatment goals: reduce thrombosis risk, control symptoms, prevent progression.

First-Line Therapies

  • Therapeutic phlebotomy: Target Hct <45% (men) / <42% (women).
  • Low-dose aspirin (81–100 mg daily): Reduces thrombotic events.

Second-Line / Cytoreductive Therapies

  • Hydroxyurea: Most common; myelosuppressive.
  • Interferon-alpha: Preferred in younger patients/pregnancy; immunomodulatory.
  • Ruxolitinib (JAK2 inhibitor): For hydroxyurea-resistant/intolerant; improves symptoms/spleen.
  • Busulfan, pipobroman: Older alkylators; higher leukemia risk.

Phosphorus-32 (³²P) – Historical Context

³²P is no longer a standard treatment. Used decades ago as intravenous radiophosphorus for cytoreduction. Abandoned due to:

  • High risk of secondary leukemia (5–15% at 10 years).
  • Prolonged marrow suppression.
  • Availability of safer oral agents (hydroxyurea, interferon).

Curative Option

Allogeneic stem cell transplant—reserved for advanced/myelofibrotic transformation or blast phase in fit patients with donors.

Monitoring

  • CBC every 3–6 months.
  • Thrombosis surveillance.
  • Screen for transformation (myelofibrosis, AML).

Treatment is individualized. Hematology consultation is essential.

NutriSystem - Related Articles